Rimegepant and BHV-3500
The intellectual property rights related to rimegepant and BHV-3500 are in-licensed from Bristol-Myers Squibb (BMS) and are covered by five families of U.S. and certain selected foreign patents.
Rimegepant was selected as the lead CGRP receptor antagonist compound for its potential best-in-class chemical profile after 10 years of internal research at BMS on this drug target. Rimegepant has been dosed in 687 subjects and studied in six clinical trials in healthy volunteers and patients with migraine that inform pharmacokinetic, metabolic interactions, safety, tolerability and efficacy of rimegepant. In a Phase 2b trial, rimegepant has demonstrated comprehensive and durable treatment effects in acute migraine.
We own several families of patent applications containing claims directed to trigriluzole and prodrugs of riluzole. These patent applications include several U.S. applications and corresponding PCT applications.
BHV-0223, a sublingual ODT form of riluzole, is licensed from Catalent and its use for treating various forms of pain, ALS and depression are currently covered in the United States by several pending U.S. patent applications, with corresponding PCT applications which we intend to nationalize in selected jurisdictions before the applicable deadlines. In addition to the patent applications we own, we have also licensed one issued patent and several pending patent applications from Yale University which provide protection for the use of riluzole in treating generalized anxiety disorder and other neurological uses, respectively. Further, we have licensed several patents from Rutgers University covering the use of riluzole for treating various forms of cancer.
BHV-5000 and lanicemine
The intellectual property rights related to BHV-5000 and lanicemine are in-licensed from AstraZeneca (AZ). We have in-licensed one patent family related to certain uses of lanicemine and a patent application family containing claims directed to BHV-5000.
BHV-5000 and lanicemine represent advances on the limitations of ketamine. While these agents are potent NMDA antagonists, their unique low-trapping pharmacology (i.e., ability to uncouple from NMDA receptor) is thought to confer limited liability for dissociative effects traditionally associated with ketamine. Additionally, BHV-5000 is orally available and, as such, is more suitable for chronic use in neuropsychiatric disorders.
The license agreement between Biohaven and AZ brings together scientific leaders in clinical glutamate research at Biohaven with AZ pharmaceutical expertise in developing a novel NMDA antagonist. Kumar Srinivasan, VP Scientific Partnering and Alliances, IMED Biotech Unit commented, “At AstraZeneca we operate in an open research environment where we collaborate with the best external partners to develop ground-breaking medicines. Biohaven has assembled a team of highly experienced scientists, and we are confident that together we will develop new treatments that can benefit patients suffering from debilitating neuropsychiatric disorders.”
Additional Licensed Patent Applications
We have also licensed a family of patent applications related to the treatment of depression with a combination of ketamine and scopolamine from Massachusetts General Hospital.